R&D channel feed – Endpoints News

R&D channel feed

Updated: DICE rolls on as lead oral IL-17 candidate meets proof-of-concept in PhI trial, sending shares higher

3 years ago

No speedy nasal rollout for Oxford/AstraZeneca’s Covid-19 jab after PhI flop

3 years ago

Immatics spotlights more early data for TCR cell therapy in solid tumors — now let's see if it lasts

3 years ago

J&J's Janssen unveils PhII ulcerative colitis data for Tremfya combo, looking to expand the drug's footprint

3 years ago

A liver disease upstart with some global connections and a new R&D strategy reaps a $30M launch round

3 years ago

The crown jewel in Merck’s $11.5B Acceleron buyout just cleared a pivotal PhIII

3 years ago

Amid already plunging use of Merck’s Covid-19 antiviral Lagevrio, preprint gives look into real world performance

3 years ago

After calling a lengthy time out on the development field, Allogene finally kicks off a landmark PhII pivotal

3 years ago

R&D acceleration: Amgen opens its second largest research site, with lab and office space for 650 staff

3 years ago

With FDA decision one month away, Provention partners with Sanofi on US marketing for type 1 diabetes drug

3 years ago

In add-on to eye disease pipeline, Boehringer pays Surrozen to acquire rights to Wnt drug

3 years ago

AstraZeneca taps two more targets from its AI partner, again in CKD and IPF

3 years ago

Ironwood's former pipeline spinout hits another speed bump, laying off 45% and turning toward the mitochondria

3 years ago

Aldeyra touts first part of PhIII for rare eye disease but questions remain as FDA meeting approaches

3 years ago

UC Davis microbiome spinout rebrands infant supplement business with nature focus

3 years ago

Eliem says earlier drug exposure issues have been resolved, drops one epilepsy indication

3 years ago

GSK touts topline win for PD-1 in head-to-head with Keytruda — while steering next big checkpoint drug into PhIII

3 years ago

Penny stock, Merck partner lays off 45% of staff to reach PhII readout by early 2023

3 years ago

Astellas, Pantherna add organ to mRNA tie-up; Rocket launches sale of six figures worth of stock

3 years ago

KalVista ends a PhII study early after patients suffer severe and life-threatening side effects

3 years ago

Penny stock player to review all options to try staying afloat after clinical trial fail

3 years ago

Tiny Vergent seals modest Series B in pursuit of cancer imaging agent

3 years ago

Pfizer’s PARP inhibitor combo treatment passes primary endpoint — but details are slim

3 years ago

Mesoblast sends in improved potency assay, looking to resubmit to FDA on acute graft-versus-host disease drug

3 years ago

First page Previous page 119 120 121122123 124 125 Next page Last page